{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:19Z","timestamp":1790788699032,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.taap.2022.116006","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:49:40Z","timestamp":1648709380000},"page":"116006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2"],"prefix":"10.1016","volume":"443","author":[{"given":"Philip","family":"Hewitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Abla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane","family":"Lignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Oeuvray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelmina","family":"Bagchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiya","family":"Bebrevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2022.116006_bb0005","article-title":"Patient related factors affecting adherence to antimalarial medication in an urban estate in Ghana","volume":"2015","author":"Amponsah","year":"2015","journal-title":"Malar. Res. Treat."},{"key":"10.1016\/j.taap.2022.116006_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002252","article-title":"A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes","volume":"3","author":"Angulo-Barturen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2022.116006_bb0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baragana","year":"2015","journal-title":"Nature."},{"key":"10.1016\/j.taap.2022.116006_bb0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1542-474X.1997.tb00325.x","article-title":"An analysis of the time-relations of electrocardiograms","volume":"2","author":"Bazett","year":"1997","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.taap.2022.116006_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.taap.2022.116006_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12936-016-1675-x","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.taap.2022.116006_bb0035","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yrtph.2017.05.009","article-title":"Current nonclinical testing paradigms in support of safe clinical trials: an IQ consortium DruSafe perspective","volume":"87","author":"Butler","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.taap.2022.116006_bb0040","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1177\/0192623309352496","article-title":"A strategy for risk management of drug-induced phospholipidosis","volume":"37","author":"Chatman","year":"2009","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.taap.2022.116006_bb0045","author":"European Medicines Agency"},{"key":"10.1016\/j.taap.2022.116006_bb0050","series-title":"ICH S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies In (vol 2019)","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.taap.2022.116006_bb0055","series-title":"ICH Topic M 3 (R2): Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. In (vol 2019)","author":"European Medicines Agency","year":"2022"},{"key":"10.1016\/j.taap.2022.116006_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.taap.2022.116006_bb0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10928-011-9198-0","article-title":"Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuation","volume":"38","author":"Grover","year":"2011","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.taap.2022.116006_bb0070","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1475-2875-8-S1-S2","article-title":"Ongoing challenges in the management of malaria","volume":"8","author":"Kokwaro","year":"2009","journal-title":"Malar. J."},{"key":"10.1016\/j.taap.2022.116006_bb0075","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.taap.2014.06.014","article-title":"Di-22:6-bis(monoacylglycerol)phosphate: a clinical biomarker of drug-induced phospholipidosis for drug development and safety assessment","volume":"279","author":"Liu","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2022.116006_bb0080","author":"M5717"},{"issue":"12","key":"10.1016\/j.taap.2022.116006_bb0085","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.taap.2022.116006_bb0090","series-title":"Guidelines for Treatment of Malaria","author":"Olumese","year":"2015"},{"key":"10.1016\/j.taap.2022.116006_bb0095","doi-asserted-by":"crossref","first-page":"13504","DOI":"10.1002\/anie.201507264","article-title":"A Quinoline Carboxamide antimalarial drug candidate uniquely targets plasmodia at three stages of the parasite life cycle","volume":"54","author":"O\u2019Neill","year":"2015","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.taap.2022.116006_bb0100","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s11095-008-9787-9","article-title":"The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms","volume":"25","author":"Sahin","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2022.116006_bb0105","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/cts.12582","article-title":"Design and conduct considerations for first-in-human trials","volume":"12","author":"Shen","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.taap.2022.116006_bb0110","author":"The Food and Drug Association (USA)"},{"key":"10.1016\/j.taap.2022.116006_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0160-5402(89)90015-6","article-title":"An improved method to correct the QT interval of the electrocardiogram for changes in heart rate","volume":"22","author":"Van de Wanter","year":"1989","journal-title":"J. Pharmacol. Methods."},{"key":"10.1016\/j.taap.2022.116006_bb0120","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1128\/AAC.00287-13","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization","volume":"57","author":"White","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.taap.2022.116006_bb0125","author":"World Health Organization"}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2200151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X2200151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:58:50Z","timestamp":1758574730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X2200151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":25,"alternative-id":["S0041008X2200151X"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2022.116006","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2022.116006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116006"}}